Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (5)	8/10/2005 11:37:57 AM
From: Luke	Read Replies (1) \| Respond to of 184

COley Pharma IPO!! Does anyone follow DVAX anymore? It's kinda quiet here... I am not sure if i am calculating this right, but the S1 says preferred converts to 78M shares, implying that Coley Pharma is priced at a valuation of $1.3 Billion??? And DVAX is barely at $100M? biospace.com Coley Pharmaceutical Group Sets Price For Initial Public Offering WELLESLEY, Mass., Aug. 10 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. today announced the initial public offering of 6,000,000 shares of its common stock at a price of $16.00 per share, before underwriting discounts and commissions. Shares of Coley's common stock will be traded on the Nasdaq National Market beginning August 10, 2005 under the trading symbol "COLY". Coley has granted the underwriters of the initial public offering a 30-day over-allotment option to purchase an additional 900,000 shares. In a separate private placement, an additional 625,000 shares will be purchased by Coley's collaboration partner, Pfizer, Inc., at $16.00 per share, under the terms of a worldwide license agreement announced with Coley in March 2005. Merrill Lynch & Co. was the book runner for the offering with J.P. Morgan acting as co-lead. Lazard and Leerink Swann are acting as co-managers for the offering. Proceeds from the offering are expected to be approximately $97,594,000 or $110,986,000 if the underwriters exercise their over-allotment option in full, after deducting the underwriting discounts and commissions and the estimated offering expenses. Copies of the final prospectus relating to the offering may be obtained by contacting Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 USA (telephone: +1.212.449.1000). A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 9, 2005. The public offering is being made by means of a written prospectus forming part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.